Ozempic & Wegovy: New Study Reveals Wider Health Benefits Beyond Weight Loss
LONDON (IT BOLTWISE) – New research indicates that GLP-1 medications, including Ozempic and Wegovy, offer health benefits extending beyond weight loss, potentially playing a key role in treating osteoarthritis, cardiovascular disease, and kidney health.
For some time, GLP-1 medications like Ozempic and Wegovy have been recognized for their ability to facilitate weight loss. However, recent studies suggest a broader range of positive health outcomes. Eric Topol, a physician and scientist, recently highlighted research demonstrating that semaglutide, the active ingredient in Ozempic, can improve knee osteoarthritis by restoring cartilage, independent of weight loss. These findings were observed in both a mouse model and a small randomized clinical trial.
The research indicates that GLP-1 medications alter the cellular metabolism in cartilage cells, shifting them from glycolysis – a less efficient energy pathway – to a more efficient oxidative metabolism. This discovery could open new avenues for treating degenerative joint diseases like osteoarthritis, according to the study.
the findings suggest positive impacts on cardiovascular health. The study revealed that 66% of the reduction in major cardiovascular events was independent of weight loss. Kidney health also appears to benefit from these medications, as they reduce protein excretion and interact directly with GLP-1 receptors in the kidneys.
In the area of liver health, study results show that 50-70% of the benefits observed in treating MASH (Metabolic Associated Steatohepatitis), a form of liver inflammation, were independent of weight loss. These medications reduce lipotoxicity and improve liver enzymes before any weight loss occurs. These findings expand the potential of semaglutide beyond metabolic diseases to include degenerative joint diseases and other health conditions.
According to a report from December 18, 2025, by mein-gleichgewicht.de, GLP-1 medications have gained significant attention in recent years, with reports of substantial weight loss and improved blood sugar levels sparking hope. However, the report also notes uncertainties regarding how these medications function, their potential side effects, and the validity of positive experiences reported in the media. The article emphasizes the importance of informed and sustainable health decisions.
A December 2025 report by NDR.de notes that Ozempic is a highly effective medication for individuals with poorly controlled Type 2 diabetes who also have coronary artery disease. The report also highlights concerns about potential shortages of the medication due to increased demand for weight loss purposes, potentially endangering patients who rely on it for diabetes management.
A July 18, 2023 article from Deutsche Apotheker Zeitung points out that both Ozempic and Wegovy contain the same active ingredient, semaglutide, but are approved for different indications, leading to price discrepancies.